Qiagen's DxS Unit to Develop Companion Dx for Pfizer Compound

Qiagen's DxS subsidiary will develop a PCR-based test to help identify ideal patients for a vaccine that Pfizer is developing for glioblastoma multiforme.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.